SCRS Announces Site Scholarships
Ellicott City, MD – SCRS announces Site Scholarships sponsored by Total Clinical Trial Management (TCTM). TCTM recognizes the pivotal role SCRS provides in enhancing site success and ensuring their sustainability. These site scholarships will be awarded to site partners identified by TCTM that are not already members of SCRS.
“SCRS has reached over 3,000 research sites and welcomes this opportunity to support more sites in achieving their fullest potential,” said Christine Pierre, President of SCRS. “TCTM has taken a position of being site-centric and by providing these scholarships they are continuing to demonstrate their commitment to being a strong site partner.”
“TCTM is an enthusiastic supporter of SCRS and their mission, and we believe the clinical research ecosystem will be enhanced by enabling the involvement and supporting the membership of more research sites in SCRS,” commented Tim Evans, Vice President, Business Development at TCTM.
About SCRS
SCRS is a global trade organization founded in 2012 which represents over 3,000 research sites in 49 countries. SCRS’ mission is to unify the voice of the global clinical research site community for greater site sustainability. SCRS has become an active partner in industry-wide initiatives and dialogues focused on improving the clinical research enterprise. Sites and the companies that sponsor or support the work conducted at clinical research sites will benefit from membership and partnership. Visit MySCRS.org.
About Total Clinical Trial Management
Total Clinical Trial Management (TCTM) is a boutique contract research organization based in Dallas, Texas. TCTM has a unique perspective on emphasizing the relationship with the clinical research site as a primary driver for successful clinical trial completion. Visit totalcro.com.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Merck Launches Phase III Trials of Once-Monthly Oral HIV PrEP Candidate MK-8527
July 14th 2025In the new EXPrESSIVE clinical trial program, Merck will evaluate MK-8527, a once-monthly, oral PrEP therapy, in populations at high risk of HIV-1 infection, including adolescent girls and women in sub-Saharan Africa.
Baxdrostat Shows Significant Blood Pressure Reduction in Phase III BaxHTN Trial
July 14th 2025In the BaxHTN Phase III study, AstraZeneca’s baxdrostat demonstrated statistically significant and clinically meaningful reductions in systolic blood pressure in patients with uncontrolled or treatment-resistant hypertension.
